Duloxetine Capsule, Delayed Release
Product Images NDC 71610-954

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71610-954). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0954 30)

Label for Duloxetine Delayed-Release capsules, 30 mg strength, containing 30 capsules. The label shows storage instructions, manufacturer Ajanta Pharma USA Inc., package by Aphena Pharma Solutions - Tennessee, LLC, and includes NDC 71610-954-30. It specifies Rx only and provides batch and expiration date fields.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier curve depicting the proportion of patients with relapse over time from randomization to relapse (in days). The chart compares two treatments: Duloxetine and placebo, showing relapse rates over approximately 200 days.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved with Duloxetine 60/120 mg once daily versus placebo. The x-axis represents percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. The graph illustrates that a higher percentage of patients improved with Duloxetine compared to placebo across various levels of pain improvement.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A Kaplan-Meier survival curve chart showing the proportion of patients with relapse over time from randomization to relapse (days). The graph compares two treatments: Duloxetine and placebo, with axis labels for time (0-300 days) and proportion of patients relapsed (0-1.0). Duloxetine shows a lower proportion of patients with relapse over time compared to placebo.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph illustrating the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The y-axis shows the percentage of patients improved, ranging from 0 to 100%, and the x-axis shows percent improvement in pain from baseline, ranging from >0 to 100%.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph depicting the percentage of patients improved over the percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo, with patient improvement percentages plotted along the vertical axis and percent pain improvement along the horizontal axis.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line chart comparing percent improvement in pain from baseline versus percentage of patients improved for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved. Duloxetine groups show higher improvement percentages than placebo at most pain improvement levels.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing the percentage of patients improved based on percent improvement in pain from baseline. It compares duloxetine dosages (120 mg, 60 mg, 20 mg once daily) versus placebo, with the x-axis representing percent improvement in pain and the y-axis representing percentage of patients improved. Duloxetine treatments show higher patient improvement than placebo across pain improvement levels.*

FDA Label Image

Figure7 (Duloxetine Fig7)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline. It shows two data series: Duloxetine 60 mg once daily (marked with crosses) and placebo (marked with circles). The graph illustrates higher percentages of patient improvement across various pain improvement thresholds for Duloxetine compared to placebo.*

FDA Label Image

Figure8 (Duloxetine Fig8)

This chart compares the percentage of patients improved versus percent improvement in pain from baseline using a baseline observation carried forward (BOCF) method. It shows data for Duloxetine 60/120 mg once daily against a placebo, illustrating patient response rates across a range of pain improvement thresholds.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved in pain from baseline (BOCF) for Duloxetine 60 mg once daily versus placebo. The x-axis shows percent improvement in pain from baseline, ranging from greater than 0 to 100 percent. The y-axis shows the percentage of patients improved, ranging from 0 to 100 percent. Duloxetine identifies a generally higher percentage of patients improved across the range compared to placebo.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of Duloxetine hydrochloride, showing the molecular arrangement including a naphthalene moiety, a thiophene ring, and the hydrochloride (HCl) salt form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.